Cargando…

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G., Durie, Brian G., Rosiñol, Laura, Mateos, Maria-Victoria, Dispenzieri, Angela, Moreau, Philippe, Kumar, Shaji, Raje, Noopur, Munshi, Nikhil, Laubach, Jacob P., O’Gorman, Peter, O’Donnell, Elizabeth, Voorhees, Peter, Facon, Thierry, Bladé, Joan, Lonial, Sagar, Perrot, Aurore, Anderson, Kenneth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620581/
https://www.ncbi.nlm.nih.gov/pubmed/37608773
http://dx.doi.org/10.3324/haematol.2022.282624
_version_ 1785130236782837760
author Richardson, Paul G.
Durie, Brian G.
Rosiñol, Laura
Mateos, Maria-Victoria
Dispenzieri, Angela
Moreau, Philippe
Kumar, Shaji
Raje, Noopur
Munshi, Nikhil
Laubach, Jacob P.
O’Gorman, Peter
O’Donnell, Elizabeth
Voorhees, Peter
Facon, Thierry
Bladé, Joan
Lonial, Sagar
Perrot, Aurore
Anderson, Kenneth C.
author_facet Richardson, Paul G.
Durie, Brian G.
Rosiñol, Laura
Mateos, Maria-Victoria
Dispenzieri, Angela
Moreau, Philippe
Kumar, Shaji
Raje, Noopur
Munshi, Nikhil
Laubach, Jacob P.
O’Gorman, Peter
O’Donnell, Elizabeth
Voorhees, Peter
Facon, Thierry
Bladé, Joan
Lonial, Sagar
Perrot, Aurore
Anderson, Kenneth C.
author_sort Richardson, Paul G.
collection PubMed
description To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patients’ prognosis worsens after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) receive optimal frontline therapy. The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has consistently demonstrated a tolerable safety profile with significant and clinically relevant benefit, including deep and durable responses with improved survival in patients with NDMM regardless of their transplant eligibility. Furthermore, comparative studies evaluating this triplet regimen against both doublet and other triplet regimens have established RVd as a standard of care in this setting based upon its remarkable and concordant efficacy. Given the breadth of clinical data, physician familiarity, inclusion in treatment guidelines, and the emerging potential of RVd-containing quadruplet regimens, RVd will likely continue as a key cornerstone of the treatment of NDMM, and its role will therefore likely continue to grow as a therapeutic backbone in the initial treatment of MM.
format Online
Article
Text
id pubmed-10620581
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-106205812023-11-03 Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma Richardson, Paul G. Durie, Brian G. Rosiñol, Laura Mateos, Maria-Victoria Dispenzieri, Angela Moreau, Philippe Kumar, Shaji Raje, Noopur Munshi, Nikhil Laubach, Jacob P. O’Gorman, Peter O’Donnell, Elizabeth Voorhees, Peter Facon, Thierry Bladé, Joan Lonial, Sagar Perrot, Aurore Anderson, Kenneth C. Haematologica Review Article To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patients’ prognosis worsens after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) receive optimal frontline therapy. The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has consistently demonstrated a tolerable safety profile with significant and clinically relevant benefit, including deep and durable responses with improved survival in patients with NDMM regardless of their transplant eligibility. Furthermore, comparative studies evaluating this triplet regimen against both doublet and other triplet regimens have established RVd as a standard of care in this setting based upon its remarkable and concordant efficacy. Given the breadth of clinical data, physician familiarity, inclusion in treatment guidelines, and the emerging potential of RVd-containing quadruplet regimens, RVd will likely continue as a key cornerstone of the treatment of NDMM, and its role will therefore likely continue to grow as a therapeutic backbone in the initial treatment of MM. Fondazione Ferrata Storti 2023-08-24 /pmc/articles/PMC10620581/ /pubmed/37608773 http://dx.doi.org/10.3324/haematol.2022.282624 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review Article
Richardson, Paul G.
Durie, Brian G.
Rosiñol, Laura
Mateos, Maria-Victoria
Dispenzieri, Angela
Moreau, Philippe
Kumar, Shaji
Raje, Noopur
Munshi, Nikhil
Laubach, Jacob P.
O’Gorman, Peter
O’Donnell, Elizabeth
Voorhees, Peter
Facon, Thierry
Bladé, Joan
Lonial, Sagar
Perrot, Aurore
Anderson, Kenneth C.
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
title Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
title_full Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
title_fullStr Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
title_full_unstemmed Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
title_short Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
title_sort clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620581/
https://www.ncbi.nlm.nih.gov/pubmed/37608773
http://dx.doi.org/10.3324/haematol.2022.282624
work_keys_str_mv AT richardsonpaulg clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT duriebriang clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT rosinollaura clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT mateosmariavictoria clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT dispenzieriangela clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT moreauphilippe clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT kumarshaji clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT rajenoopur clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT munshinikhil clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT laubachjacobp clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT ogormanpeter clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT odonnellelizabeth clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT voorheespeter clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT faconthierry clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT bladejoan clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT lonialsagar clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT perrotaurore clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma
AT andersonkennethc clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma